Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TAS2R46 | P59540 | 4/20 | 0.32 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.32 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494186 | 1.00 | ATM (1.00) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL29694449 | 0.81 | ATM (0.67) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL29625296 | 0.71 | ATM (0.55) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL31058464 | 0.68 | ATM (0.51) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL20877882 | 0.59 | ICAM1 (0.52) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL27949123 | 0.59 | RECQL (0.48) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL4998367 | 0.59 | RECQL (0.48) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL23007994 | 0.58 | ICAM1 (0.44) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL21475315 | 0.58 | ICAM1 (0.44) | ATMCYP3A4RECQLCYP19A1ICAM1 | |
| SCHEMBL21475309 | 0.58 | ICAM1 (0.44) | ATMCYP3A4RECQLCYP19A1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027184-A1 | METHODS AND DEVICES FOR PROMOTING NERVE GROWTH AND REGENERATION | UNIV TEXAS (US) | 2026-01-29 | — | — | US | claimed |
| US-12428623-B2 | Generation of midbrain-specific organoids from human pluripotent stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-09-30 | — | — | US | claimed |
| US-20250170178-A1 | METHODS AND PRODUCTS FOR CULTURING T CELLS AND USES THEREOF | Quell Therapeutics Limited (GB) | 2025-05-29 | — | — | US | claimed |
| EP-3430132-B1 | GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY SCIENCE TECH & RES (SG) | 2025-04-30 | — | — | EP | claimed |
| EP-4496883-A1 | METHODS AND PRODUCTS FOR CULTURING T CELLS AND USES THEREOF | Quell Therapeutics Limited (GB) | 2025-01-29 | — | — | EP | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | claimed |
| WO-2024194649-A1 | ENGINEERED T CELLS AND USES THEREOF | Quell Therapeutics Limited (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240270855-A1 | NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD (PT) | 2024-08-15 | — | — | US | claimed |
| EP-4347645-A1 | NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT | Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation (PT) | 2024-04-10 | — | — | EP | claimed |
| WO-2023180690-A1 | METHODS AND PRODUCTS FOR CULTURING T CELLS AND USES THEREOF | Quell Therapeutics Limited (GB) | 2023-09-28 | — | — | WO | claimed |
| US-11666684-B2 | Multilayered cell sheet of neural crest stem cells and method of preparing the same | INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-06-06 | — | — | US | claimed |
| US-11628227-B2 | Mineral coated microparticles for gene delivery in chronic wound therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-04-18 | — | — | US | claimed |
| US-20230047766-A1 | MEDICAL DEVICE, THERAPEUTIC METHOD, AND DIAGNOSTIC METHODS FOR THE TREATMENT AND PREVENTION OF VASOSPASM | Sylvian Inc. (JP) | 2023-02-16 | — | — | US | claimed |
| WO-2022254255-A1 | NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT | FUNDACAO D. ANNA DE SOMMERCHAMPALIMAUD E DR. (PT) | 2022-12-08 | — | — | WO | claimed |
| WO-2022108372-A1 | METHOD FOR MANUFACTURING BRAIN ORGANOIDS AND SCREENING METHOD FOR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES USING SAME | 서울대학교산학협력단 | 2022-05-27 | — | — | WO | claimed |
| EP-4736848-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF | Shanghai Regenelead Therapies Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | AMUNIX PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022020388-A1 | COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS | AMUNIX PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027184-A1 | METHODS AND DEVICES FOR PROMOTING NERVE GROWTH AND REGENERATION | NGF, DCX, NTRK2 | ATM 3723/4885CYP3A4 4885/4885RECQL 4221/4885 |
| US-12617815-B2 | Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same | SPPL2B, PTMS, ANPEP | ATM 4025/4885CYP3A4 4219/4885RECQL 2148/4885 |
| US-20240270855-A1 | NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT | CRHR2, VIPR2, HCRTR2 | ATM 2516/4885CYP3A4 4611/4885RECQL 4424/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | ATM 1927/4885CYP3A4 4859/4885RECQL 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.